Tests a game-based attention training app in children with sickle cell disease
Tests a tablet attention game at home in children with sickle cell disease.
Key facts
- Who runs it
- Children's National Research Institute
- Where
- Washington D.C., United StatesSee the site
- Trial code
- Registry title
- Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 20 Dec 2022
- Planned end
- Dec 2025
- Type of study
- Interventional
- Treatments tested
- EndeavorRx
- Record updated
- 10 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 8-16 with sickle cell disease who get regular monthly blood transfusions and have attention problems. It tests a tablet game that trains attention.
- Age
- 8-16 years
- Sex
- Boys and girls
- Disease stage
- Sickle cell disease, on monthly blood transfusions for at least 3 months in a row.
- Earlier treatment
- Monthly blood transfusions, given consistently for at least 3 months.
- Biomarker or test result
- To start the training, a T-score above the 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3), or for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V).
Main reasons for not taking part
- Estimated Intelligence Quotient below 70
- Motor, visual or hearing problem that prevents computer use
- Known mental health condition that rules out or takes priority over cognitive training
- History of photosensitive seizures
- Not enough English fluency
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- diagnosis of SCD
- ages 8-16 years
- maintained on monthly blood transfusions consistently for at least 3 months
- patients will be proceed to the intervention phase only if they have a T-score > 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) or a T-score > 75th percentile for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V)
Who cannot take part
- motor, visual, or auditory impairment that prevents computer use
- known diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in cognitive training
- history of photosensitive seizures
- estimated Intelligence Quotient < 70
- insufficient English fluency
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 16 years old?
Where in United States
- Children's National HospitalWashington D.C., United StatesContact: Steven Hardy, PhDTaking people
About the trial
What the trial wants to find out
Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.
The group in the trial
- EndeavorRxTreatment being tested
Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
- Plain-language title
- Tests a game-based attention training app in children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05099874, who can take part
- Record updated
- 10 January 2025